ELENA G. SAYKALY P.A.
Prescription History 1073817839
Physician Assistant - Surgical in Culpeper, VA

NPI Status: Active since January 07, 2011

Contact Information

541 SUNSET LN
SUITE 103
CULPEPER, VA
ZIP 22701
Phone: (540) 825-2600
Fax: (540) 825-4026

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ELENA G. SAYKALY P.A., an active Surgical specialist practicing in Culpeper, VA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 99 documented patient claims. Among these therapy options, the most frequently utilized medication is Meloxicam, which accounts for 42 claims alone.

Medication Index

No matching medications currently found on file.

Celecoxib

Generic Formulation: CelecoxibSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 23
30-Day Fills 34.0
Days Supply 1,005
VA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills54.5
Peer Average Days Supply1,600
Conservative Utilization

This provider writes prescriptions for this formulation 30.3% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,820.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$79.14

State Avg Cost Per Claim

$52.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.

Therapeutic Applications

This medication is a nonsteroidal anti-inflammatory drug (NSAID), specifically a COX-2 inhibitor, which relieves pain and swelling (inflammation). It is used to treat arthritis, acute pain, and menstrual pain and discomfort. The pain and swelling relief provided by this medication helps you perform more of your normal daily activities. If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section. This drug works by blocking the enzyme in your body that makes prostaglandins. Decreasing prostaglandins helps to reduce pain and swelling.

Cephalexin

Generic Formulation: CephalexinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 88
VA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills30.0
Peer Average Days Supply306
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $102.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.32

State Avg Cost Per Claim

$8.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Gabapentin

Generic Formulation: GabapentinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 585
VA State Average Benchmarks
Peer Average Claims89.0
Peer Average 30-Day Fills132.3
Peer Average Days Supply3,808
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.5% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $103.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.17

State Avg Cost Per Claim

$19.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Meloxicam

Generic Formulation: MeloxicamSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 42
30-Day Fills 104.0
Days Supply 3,120
VA State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills83.0
Peer Average Days Supply2,456
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $266.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.34

State Avg Cost Per Claim

$6.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

Meloxicam is used to help relieve moderate to severe pain. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling or pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ELENA G. SAYKALY P.A. provides transparency into local medical care patterns within Culpeper, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Surgical** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.